Replies to post #11672 on Sorrento Therapeutics Inc (SRNE)

[runcaly]

SAN DIEGO, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") previously announced that its partner Escugen Biotechnology Co, Ltd. (“Escugen”) and Sorrento’s subsidiary Levena (Suzhou) Biopharma Co., Ltd. (“Levena”) had received an approval letter from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for its Application for Clinical Trial (Acceptance No. CXSL2101069) of Recombinant Humanized Anti-Trop2 Mab-SN38 Conjugate. Today Sorrento announces that the US FDA has given clearance to proceed with clinical trials in cancer patients with relapsed or refractory solid tumors.

[dia76ca]

Glad to see the RTX treatment for intractable cancer pain advancing. It was this indication and the cancer drugs that first got me interested in Sorrento. And RTX has several other very large and important applications. This is very good news for cancer patients and their families!

[1776club]

Phase 3 start 2024? Hope SP102 get approval in 2022 and Sorrento owns more of it than Dr. Ji.